The pso Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the pso Hub cannot guarantee the accuracy of translated content. The pso and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB: For educational content and news updates.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View pso content recommended for you
Ixekizumab post-marketing surveillance in Japanese patients with psoriasis and PsA
Psoriasis is a chronic inflammatory disease that can be difficult to treat and is associated with significant disease burden, particularly in rarer forms of psoriasis such as generalized pustular psoriasis; which can be fatal if inadequately treated. A multicenter post-marketing study was conducted from 2016 to 2022 to evaluate the efficacy and safety of ixekizumab in Japanese patients with psoriasis for up to 52 weeks, with the incidence of serious infections and malignancies measured for up to 3 years.1 A total of 804 patients were included in the analysis, with 72.9%, 37.7%, 7.8%, and 3.7% having psoriasis vulgaris, psoriatic arthritis, pustular psoriasis, and erythrodermic psoriasis, respectively (some patients had multiple subtypes).1 Results were published in The Journal of Dermatology by Torii et al.1
|
Key learnings |
| Ixekizumab demonstrated significant clinical effectiveness in treating moderate to severe psoriasis in Japanese patients. A high proportion of patients achieved PASI 75/90/100 responses, indicating near-complete or complete skin clearance. |
| Sustained efficacy was observed over the study duration, reinforcing ixekizumab as a viable long-term treatment option for psoriasis management. In addition, improvements were noted in DLQI scores from baseline to Week 52. |
| The safety profile was consistent with previous global studies. AEs were reported in 25.3% of patients. Common AEs included nasopharyngitis, injection-site reactions, and upper respiratory tract infections. No new safety signals were identified. |
| These findings support ixekizumab as an effective biologic therapy for patients with psoriasis, aligning with international treatment guidelines, and suggest that utilizing early biologic intervention in eligible patients can lead to rapid disease control. |
Abbreviations: AE, adverse event; DLQI, Dermatology Life Quality Index; PASI, Psoriasis Area and Severity Index.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
